E

Insights on targeting the oncogene SHP2

How do we improve responses to EGFR, BRAF & KRAS inhibitors? One way may be add in a SHP2 inhibitor - we look at why this target matters and which competitors are in this niche.

October 30, 2019
E

New path to market opportunity for Kura in SCCHN

KRAS isn't the only RAS mutation seeing progress - there's also HRAS which is now druggable thanks to Kura Oncology's tipifarnib

October 29, 2019
E

What do we learn from a first look at Mirati’s KRAS G12C inhibitor MRTX849?

Dr Pasi Janne presented the initial first-in-man data from Mirati's KRAS G12C inhibitor MRTX849 - what did we learn?

October 28, 2019
E

Targeting NRG1 Gene Fusions

What did we learn at #Targets19 about targeting NRG1 gene fusions with MCLA-128?

October 27, 2019
E

Further issues surrounding RAS inhibition in oncology

On dosing issues, read across from BRAF in CRC, what is SOS1 and a look at future combinations...

October 25, 2019
E

A novel approach to targeting BRAF and KRAS mutant cancers

How do we go about targeting KRAS mutations beyond G12C? Here's one elegant way that is promising yet very early in which it could be approached...

October 23, 2019
E

Can STING agonists promote cancer metastasis?

Can STING agonists promote cancer metastasis in some patients? That's one of the key questions from new research linking chromosomal instability with tumor metastasis through activation of the cGAS-STING pathway.

January 23, 2018
E

What can genomics and tumours teach us about cancer drug development?

A look at loss of heterozygosity and what it means for new lung cancer therapies

November 20, 2017
E

TARGETS17 Gems from the Poster Halls

A look at new targets, molecules and approaches to cancer research from #TARGETS17 in Philly

November 7, 2017
E

Some simply stunning cancer research for Journal Club

Science Fridays: A look at six key studies recently published on cancer research that BSB readers can learn from.

November 3, 2017
E

Key Highlights from Day 3 at AACR-NCI-EORTC TARGETS17

Highlights from Day 3 of the AACR-NCI-EORTC Molecular Targets meeting in Philadelphia

October 29, 2017
E

Highlights from Day 2 AACR-NCI-EORTC #TARGETS17

A look at some of the important data coming out of Day 2 of #Targets17 in Philadelphia

October 28, 2017
E

Key Highlights From AACR Molecular Targets Day 1

Commentary on Day 1 of 2017 AACR NCI EORTC Molecular Targets and Cancer Therapeutics Conference in Philadelphia

October 27, 2017
E

Blueprint Shows Promise in GIST and HCC

Targeted therapies aren't dead yet - oncogenic drivers are still important in many cancers. Here we look at progress in GIST, systemic mastocytosis and HCC...

February 16, 2017
E

How to improve response rates with targeted therapies in oncology

Exploring clinical trials with targeted therapies, including PARP and ATR inhibitors and combination approaches

February 2, 2017
E

A manifesto for immuno-oncology research

A draft manifesto for IO in cancer research and what we need to learn

February 1, 2017
E

ASH16 Update on BCMA CAR T cell therapies

A look at the new various developments in CAR Therapies targeting BCMA in multiple myeloma

December 14, 2016
E

Gems from the Poster Halls at EORTC-NCI-AACR in Munich

Gems from the Poster Hall on Wednesday at EORTC-NCI-AACR Molecular Targets meeting in Munich

November 30, 2016
E

Making breast cancer cells become normal again

Can we revert the mutant phenotype in breast cancer and return to a normal, non cancerous phenotype?

November 30, 2016
E

ENA 2016 Immunotherapy Symposium Highlights

Highlights from the Charles River Immunotherapy Symposium in Munich, 2016

November 29, 2016
E

AstraZeneca’s AZD9291 osimertinib is approved as Tagrisso

AstraZeneca's AZD9291 was approved by the FDA in EGFR T90M mutation positive lung cancer today and is now known as osimertinib or Tagrisso.

November 13, 2015
E

What’s Hot at AACR #Targets15 in Boston?

Preview of the key topics coming up at the AACR-NCI-EORTC Molecular Targets meeting in Boston, including Pasi Janne's interesting data on T790M negative NSCLC...

October 27, 2015
E

Potential of Rociletinib in T790M negative NSCLC

Clovis have observed responses in T790M positive AND negative lung cancer with rociletinib - implications for the commercial opportunity are discussed in this post.

January 28, 2015
E

UCL Drives CD19 CAR T Cell Therapy Forward in Europe

University College London (UCL) is leading the way in European clinical trials of CAR T Cell therapies that target CD19.

April 14, 2015
E

EORTC Molecular Targets – new developments in Ovarian Cancer

Ovarian cancer has lagged behind other solid tumours in terms of development, but this situation may soon change with promising new agents being developed

November 19, 2014
E

Rociletinib versus AZD9291 race to market heats up in T790M lung cancer at EORTC

Clovis present their Phase 2 data with the new rociletinib formulation at EORTC-AACR-NCI in Barcelona

November 19, 2014
E

Agios IDH1 Inhibitor AG-120 shows promise in AML $AGIO

Agios AG-120 IDH1 Inhibitor shows promise in acute myeloid leukemia (AML) according to data to be presented at the EORTC-AACR-NCI Molecular Targets and Cancer Therapeutics Symposium in Barcelona

November 18, 2014
E

Update on overcoming resistance in metastatic melanoma

What new clinical approaches are being investigated to overcome resistance in melanoma?

March 20, 2014
E

CDK inhibitors: will palbociclib and LEE011 make it to market in breast cancer?

Cell cycle inhibitors have been shown to have utility in cancer treatment. A new subclass is emerging to target CDK4/6 with more specificity and less toxicity.

March 19, 2014
E

The future of cancer research – Part 2

The huge wealth of research at the AACR-NCI-EORTC Boston conference provided a great learning environment of where future research with TKIs is likely to be heading...

November 6, 2013
E

The future of cancer research – what I learned from the AACR Targets meeting Part 1

The cancer landscape is rapidly changing, in more ways than people realise. Diagnostics are also of increasing importance in helping to decide which therapies patients should receive to optimize treatment.

November 5, 2013
E
Dr Deepak Sampath, Genentech

Gazyva and ABT-199 in CLL & NHL – an interview with Genentech’s Deepak Sampath

An interview with Dr Deepak Sampath from Genentech on the rational for combining obinutuzumab (GA101) with GDC-0199 (ABT-199) for the treatment of B-cell hematological malignancies such as CLL & non Hodgkin’s lymphoma (NHL).

November 1, 2013
E

New insights on checkpoint inhibitors and CART in CLL and solid tumors

An update on checkpoint inhibitors and CART from the AACR-NCI-EORTC Molecular Targets meeting - a lot of exciting possibilities are emerging!

October 25, 2013
E

Abraxane kills potential of MLN0264 in pancreatic cancer

Following the FDA approval of Abraxane, MLN0264, a novel ADC targeting GCC, may no longer have potential as a therapeutic in pancreatic cancer.

October 21, 2013
E

Cerulean CRLX101 Challenges and Opportunities

Cerulean are developing a novel nanopharmaceutical that targets HIF1-alpha and is synergistic with anti-angiogenic drugs for RCC and Ovarian cancers.

October 21, 2013
E

AstraZeneca ramps up AZD9291 lung cancer clinical development

At the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics conference, Susan Galbraith, M.D, Ph.D. Head of the Oncology Innovative Medicines Unit at AstraZeneca discussed the rapid development of AZD9291, a potent and selective third-generation EGFR inhibitor.

October 20, 2013
E

Pfizer next gen ALK inhibitor PF-06463922 could replace Xalkori

Preclinical data for PF-06463922 (Pfizer), a next generation ALK inhibitor, with potency for all known Crizotinib ALK resistant mutants and ability to cross the blood brain barrier was presented today at the 2013 International Conference on Molecular Targets and Cancer Therapeutics in Boston.

October 20, 2013
E

A quick preview of the AACR Molecular Targets Conference

Preview of some of the interesting non-embargoed abstracts from the ACCR-NCI-EORTC Molecular Targets conference in Boston

October 15, 2013
E
Cambridge from Bay Bay Boston

Preview of 2013 AACR Molecular Targets Conference in Boston

Preview of 2013 AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference in Boston. This is a "must attend" meeting for anyone interested in cancer drug development.

October 11, 2013